Literature DB >> 17053057

ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men.

Chan K N K Chion1, Carine J M Doggen, James T B Crawley, David A Lane, Frits R Rosendaal.   

Abstract

Von Willebrand factor (VWF) mediates the tethering/adhesion of platelets at sites of vascular injury. This function depends on its multimeric size, which is controlled by ADAMTS13. We measured plasma ADAMTS13 and VWF antigen levels by enzyme-linked immunosorbent assay (ELISA) in a large population-based case-control study (Study of Myocardial Infarctions Leiden [SMILE]), consisting of 560 men with a first myocardial infarction (MI) and 646 control subjects. Although ABO blood groups influenced VWF levels, they had no influence on ADAMTS13. Furthermore, there was no relationship between plasma ADAMTS13 and VWF levels. Similar to VWF, the estimated risk of MI was increased for every quartile of ADAMTS13 when compared to the lowest quartile (odds ratio, 1.5-1.6). If confirmed, the association of ADAMTS13 with MI may suggest an unexpected mechanistic action of ADAMTS13.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053057     DOI: 10.1182/blood-2006-07-038166

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity.

Authors:  Rens de Groot; David A Lane; James T B Crawley
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

2.  Noninvasive Evaluation of No-Reflow Phenomenon.

Authors:  Albert J Sinusas
Journal:  Circ Cardiovasc Imaging       Date:  2018-11       Impact factor: 7.792

3.  Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels.

Authors:  Qianyi Ma; Paula M Jacobi; Brian T Emmer; Colin A Kretz; Ayse Bilge Ozel; Beth McGee; Chava Kimchi-Sarfaty; David Ginsburg; Jun Z Li; Karl C Desch
Journal:  Blood Adv       Date:  2017-06-19

4.  Clinical measurement of von Willebrand factor by fluorescence correlation spectroscopy.

Authors:  Richard Torres; Jonathan R Genzen; Michael J Levene
Journal:  Clin Chem       Date:  2012-03-26       Impact factor: 8.327

Review 5.  Cardiac fibrosis in regenerative medicine: destroy to rebuild.

Authors:  Gianluca Lorenzo Perrucci; Erica Rurali; Giulio Pompilio
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 6.  Regulation of VWF expression, and secretion in health and disease.

Authors:  Yaozu Xiang; John Hwa
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

7.  Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.

Authors:  Anwar Al-Awadhi; Adekunle Adekile; Rajaa Marouf
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

8.  ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice.

Authors:  Chintan Gandhi; David G Motto; Melissa Jensen; Steven R Lentz; Anil K Chauhan
Journal:  Blood       Date:  2012-09-14       Impact factor: 22.113

9.  High frequency of acquired ADAMTS13 deficiency after hemolysis in Hemiscorpius Lepturus (scorpion) stung children.

Authors:  Ehsan Valavi; Ali Ahmadzadeh; Parisa Amoori; Aidin Daneshgar
Journal:  Indian J Pediatr       Date:  2013-07-28       Impact factor: 1.967

10.  A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF.

Authors:  Sara Zanardelli; Alain C K Chion; Evelyn Groot; Peter J Lenting; Thomas A J McKinnon; Mike A Laffan; Michelle Tseng; David A Lane
Journal:  Blood       Date:  2009-07-08       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.